摘要
观察了普萘洛尔和血管紧张素Ⅱ(AT-Ⅱ)对胃癌单克隆抗体3H11和丝裂霉素(MMC)交联物导向治疗的增强作用。在荷瘤裸鼠体内观察,交联物的抑瘤率达50％,联合应用普萘洛尔或AT-Ⅱ,可使抑瘤率分别提高到79％和60％。从^(131)Ⅰ-3H11,在荷瘤裸鼠体内的生物学分布实验中也看到,普萘洛尔或AT-Ⅱ均能提高肿瘤组织对^(131)Ⅰ-3H11的摄取量。此结果表明,血管活性物质确可通过改善肿瘤血管的血流灌注,增加肿瘤内交联物含量,增强导向治疗的疗效。
The effects of vasoactive agents propranolol hydrochloride and angiotensin (AT-Ⅱ) on improving the directed therapy of cancer with the use of conjugate of gastric cancerantibody (3H11) and mitomycin C (MMC) were studied. The antibody activity of the conjugate(3H11-HSA-MMC) was retained with the molecular ratio of 1:2:60. In tests with tumor-bearingnude mice, the tumor inhibitory rate of the conjugate alone was found to be 50%, while in conjugatetreated mice that also received propranolol or AT-II the tumor inhibitory rate were 79% and 60%,respectively. In tumor-bearing nude mice given (131)~I-3H11 both propranolol and AT-Ⅱ increased thetumor uptake of (131)~I-3H11. These results indicate that these vasoactive agents can change the tissueperfusion ratio via the effect on tumor blood vessels and increase the access of the conjugate to tumor,thereby, enhancing the effectiveness of tumor directed therapy with the use of conjugates.
出处
《药学学报》
CAS
CSCD
北大核心
1992年第12期891-894,共4页
Acta Pharmaceutica Sinica
关键词
单克隆抗体
丝裂霉素
抗癌药
Monoclonal antibidy
Mitomycin C
Conjugate
Propranolol hydrochloride
Angiotensin Ⅱ
